Skip to main content

Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial.

Publication ,  Journal Article
McClellan, TR; Motosugi, U; Middleton, MS; Allen, BC; Jaffe, TA; Miller, CM; Reeder, SB; Sirlin, CB; Bashir, MR
Published in: Radiology
February 2017

Purpose To determine, in a multicenter double-blinded placebo-controlled trial, whether maximal hepatic arterial phase breath-holding duration is affected by gadoxetate disodium administration. Materials and Methods Institutional review board approval was obtained for this prospective multi-institutional HIPAA-compliant study; written informed consent was obtained from all subjects. At three sites, a total of 44 volunteers underwent a magnetic resonance (MR) imaging examination in which images were acquired before and dynamically after bolus injection of gadoxetate disodium, normal saline, and gadoterate meglumine, administered in random order in a single session. The technologist and volunteer were blinded to the agent. Arterial phase breath-holding duration was timed after each injection, and volunteers reported subjective symptoms. Heart rate (HR) and oxygen saturation were monitored. Images were independently analyzed for motion artifacts by three radiologists. Arterial phase breath-holding duration and motion artifacts after each agent were compared by using the Mann-Whitney U test and the McNemar test. Factors affecting the above outcomes were assessed by using a univariate, multivariable model. Results Arterial phase breath holds were shorter after gadoxetate disodium (mean, 32 seconds ± 19) than after saline (mean, 40 seconds ± 17; P < .001) or gadoterate meglumine (43 seconds ± 21, P < .001) administration. In 80% (35 of 44) of subjects, arterial phase breath holds were shorter after gadoxetate disodium than after both saline and gadoterate meglumine. Three (7%) of 44 volunteers had severe arterial phase motion artifacts after gadoxetate disodium administration, one (2%; P = .62) had them after gadoterate meglumine administration, and none (P = .25) had them after saline administration. HR and oxygen saturation changes were not significantly associated with contrast agent. Conclusion Maximal hepatic arterial phase breath-holding duration is reduced after gadoxetate disodium administration in healthy volunteers, and reduced breath-holding duration is associated with motion artifacts. © RSNA, 2016.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Radiology

DOI

EISSN

1527-1315

Publication Date

February 2017

Volume

282

Issue

2

Start / End Page

361 / 368

Location

United States

Related Subject Headings

  • Prospective Studies
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Meglumine
  • Male
  • Magnetic Resonance Imaging
  • Liver
  • Injections, Intravenous
  • Humans
  • Healthy Volunteers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McClellan, T. R., Motosugi, U., Middleton, M. S., Allen, B. C., Jaffe, T. A., Miller, C. M., … Bashir, M. R. (2017). Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial. Radiology, 282(2), 361–368. https://doi.org/10.1148/radiol.2016160482
McClellan, Taylor R., Utaroh Motosugi, Michael S. Middleton, Brian C. Allen, Tracy A. Jaffe, Chad M. Miller, Scott B. Reeder, Claude B. Sirlin, and Mustafa R. Bashir. “Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial.Radiology 282, no. 2 (February 2017): 361–68. https://doi.org/10.1148/radiol.2016160482.
McClellan TR, Motosugi U, Middleton MS, Allen BC, Jaffe TA, Miller CM, et al. Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial. Radiology. 2017 Feb;282(2):361–8.
McClellan, Taylor R., et al. “Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial.Radiology, vol. 282, no. 2, Feb. 2017, pp. 361–68. Pubmed, doi:10.1148/radiol.2016160482.
McClellan TR, Motosugi U, Middleton MS, Allen BC, Jaffe TA, Miller CM, Reeder SB, Sirlin CB, Bashir MR. Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial. Radiology. 2017 Feb;282(2):361–368.

Published In

Radiology

DOI

EISSN

1527-1315

Publication Date

February 2017

Volume

282

Issue

2

Start / End Page

361 / 368

Location

United States

Related Subject Headings

  • Prospective Studies
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Meglumine
  • Male
  • Magnetic Resonance Imaging
  • Liver
  • Injections, Intravenous
  • Humans
  • Healthy Volunteers